Summary & Overview
CPT 81270: JAK2 Mutation Detection Laboratory Test
CPT code 81270 represents a clinical laboratory molecular test to detect the common JAK2 gene change (commonly the V617F mutation). This test has national clinical significance because detection of JAK2 mutations informs diagnosis and disease classification for myeloproliferative disorders, guiding downstream diagnostic workflows and potential therapeutic decision-making. The code is used broadly by hospital and independent clinical laboratories that perform molecular diagnostic assays.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what CPT code 81270 represents, how it is reported by laboratories, typical sites of service, and the context in which it is ordered. The publication outlines benchmark topics and payer consideration themes relevant to molecular testing reimbursement and coverage policy for a nationally relevant audience.
This summary provides clinical context for the test, clarifies the service type and typical site of service, and indicates where readers can expect to find payer-related coverage patterns, coding guidance, and benchmark discussions. Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and related codes is noted where applicable.
Billing Code Overview
CPT code 81270 describes a laboratory test performed by a clinical laboratory to detect a common somatic change in the Janus kinase 2 (JAK2) gene. This assay identifies the presence of the JAK2 V617F mutation, a molecular alteration associated with myeloproliferative neoplasms.
Service type: Molecular diagnostic testing / laboratory procedure
Typical site of service: Clinical laboratory or hospital laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents to a hematology clinic with persistent erythrocytosis and thrombocytosis noted on routine labs. The hematologist orders molecular testing for the JAK2 V617F mutation to evaluate for a myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia. Blood is collected in an EDTA tube at the outpatient clinic or hospital phlebotomy, labeled, and sent to the molecular diagnostics laboratory. The laboratory analyst performs the technical assay (e.g., PCR or allele-specific testing) to detect the common JAK2 gene change per CPT 81270. Results are reported to the ordering provider; if positive, the clinician integrates the finding with clinical criteria and other studies (CBC, bone marrow biopsy, erythropoietin level) to establish diagnosis and guide management. Typical sites of service include hospital outpatient laboratories, independent clinical laboratories, and hospital inpatient laboratory services when testing is ordered during an admission.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation component, if applicable for anatomic pathology or consultative interpretation associated with molecular testing reports. |